Related Experiment Video
Updated: Sep 12, 2025

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor
Published on: October 26, 2017
A ferrocene-containing analogue of the MCU inhibitor Ru265 with increased cell permeability
Zhouyang Huang1, Jesse A Spivey1, Samantha N MacMillan1
1Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, United States.
Abstract:
The mitochondrial calcium uniporter (MCU) is a transmembrane protein that mediates mitochondrial calcium (mCa2+) uptake. Inhibitors of the MCU are of interest for their applications as tools to study the role of mCa2+ uptake on cellular function. In this study, we report two potent MCU inhibitors, [Ru2(μ-N)(NH3)8(FcCO2)2](OTf)3 (RuOFc, Fc = ferrocene, OTf = triflate) and [Ru2(μ-N)(NH3)8(PhCO2)2](OTf)3 (RuOBz). These compounds are analogues of the previously reported inhibitor [Ru2(μ-N)(NH3)8(Cl)2](Cl)3 (Ru265) that has been derivatized with ferrocenecarboxylate and benzoate ligands, respectively. Both compounds were synthesized and fully characterized by NMR spectroscopy, infrared spectroscopy, and X-ray crystallography. Under physiological conditions, RuOFc and RuOBz aquate with half-lives of 2.9 and 6.5 h, respectively, to produce [Ru2(μ-N)(NH3)8(H2O)2](OTf)5 (Ru265') and the free carboxylates. Cyclic voltammetry of RuOFc in N,N'-dimethylformamide (DMF) reveals a prominent reversible 2e- transfer event at 0.64 V vs SCE, corresponding to the simultaneous oxidation of both ferrocene-containing axial ligands. All three complexes also exhibit irreversible Ru-based reductions at potentials below -1 V vs SCE. DFT calculations of Ru265', RuOFc, and RuOBz confirm that the redox activity of RuOFc arises from the ferrocene ligands. Furthermore, LUMO energies of the three compounds correlate with their irreversible reduction potentials. A systematic comparison on the biological properties of Ru265, RuOFc, and RuOBz was carried out. Both RuOFc and RuOBz inhibit mCa2+ uptake in permeabilized HEK293T cells, but are 5-7 fold less potent than Ru265. In intact cells, RuOBz is taken up by cells and inhibits the MCU to a similar extent as Ru265. RuOFc, however, exhibits a 10-fold increase in cellular uptake over Ru265, which in turn also leads to a modest enhancement in MCU-inhibitory activity in intact cells. Moreover, in contrast to Ru265, RuOFc is cytotoxic to HEK293T and HeLa cells with 50% growth inhibitory concentration values of 23.2 and 33.9 μM, respectively, a property that could be leveraged to develop MCU-targeting anticancer agents. These results establish RuOFc as a potent MCU inhibitor and another example of how axial ligand functionalization of Ru265 can lead to new compounds within this class with diverse physical and biological properties.
Insights
Two novel ruthenium complexes, RuOFc and RuOBz, function as mitochondrial calcium uniporter (MCU) inhibitors. RuOFc shows enhanced cellular uptake and cytotoxicity, suggesting potential for MCU-targeting anticancer therapies.
Area of Science:
- Inorganic Chemistry
- Biochemistry
- Cell Biology
Background:
- The mitochondrial calcium uniporter (MCU) regulates mitochondrial calcium uptake, a critical process in cellular function.
- Inhibitors of the MCU are valuable tools for investigating the role of mitochondrial calcium (mCa2+).
Purpose of the Study:
- To synthesize and characterize novel MCU inhibitors, RuOFc and RuOBz, as analogues of Ru265.
- To evaluate the physical, chemical, and biological properties of these new ruthenium complexes.
Main Methods:
- Synthesis and full characterization (NMR, IR, X-ray crystallography) of RuOFc and RuOBz.
- Assessment of aquation kinetics and electrochemical properties (cyclic voltammetry, DFT calculations).
- Evaluation of MCU inhibition in permeabilized and intact cells, along with cellular uptake and cytotoxicity assays.
Main Results:
- RuOFc and RuOBz were successfully synthesized and characterized, exhibiting distinct aquation rates and electrochemical profiles.
- Both compounds inhibit mCa2+ uptake in cells, with RuOFc demonstrating significantly higher cellular uptake and cytotoxicity.
- RuOFc's redox activity is attributed to its ferrocene ligands, as confirmed by DFT calculations.
Conclusions:
- RuOFc and RuOBz are potent MCU inhibitors with tunable properties based on axial ligand modification.
- RuOFc's enhanced cellular uptake and cytotoxicity present a promising avenue for developing MCU-targeting anticancer agents.

